Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Net Income : $-559 Mil (TTM As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Teva Pharmaceutical Industries's Net Income for the three months ended in Dec. 2023 was $429 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-559 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.38.

Teva Pharmaceutical Industries Net Income Historical Data

The historical data trend for Teva Pharmaceutical Industries's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Net Income Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income

Get a 7-Day Free Trial

-999.00

-3,990.00

417.00

-2,446.00

-559.00

Teva Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income	Get a 7-Day Free Trial															-1,314.00	-205.00	-863.00	80.00	429.00

Teva Pharmaceutical Industries Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Teva Pharmaceutical Industries's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-624	+	7	+	0	+	58
=	-559

Teva Pharmaceutical Industries's Net Income for the quarter that ended in Dec. 2023 is calculated as

	Net Income		(Q: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	473	+	-41	+	0	+	-3
=	429

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-559 Mil.

Teva Pharmaceutical Industries (NYSE:TEVA) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Teva Pharmaceutical Industries's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

Earnings per Share (Diluted) (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(429	-	0)	/	1119.000
	=	0.38

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Teva Pharmaceutical Industries Net Income Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Executives

Dov Bergwerk	officer: Acting Chief Legal Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif	officer: EVP, Chief Financial Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss	officer: Chief Accounting Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant	officer: EVP, Business Development	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs	officer: EVP Global Marketing&Portfolio	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape	officer: Executive VP Global Operations	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark	officer: Exec. VP Chief Legal Officer	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell	officer: Exec. VP, European Commercial	5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis	officer: President and CEO	IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir	officer: Executive VP, Global R&D	400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani	officer: EVP,Global Marketing&Portfolio	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks	director	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX